Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Early prediction of phenotypic severity in Citrullinemia Type 1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Habitual sleep disturbances and migraine: a Mendelian randomization study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The impact of gender, puberty, and pregnancy in patients with POLG disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Responsiveness of outcome measures in myotonic dystrophy type 1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Treatment of monogenic disorders with viral transduced haematopoietic stem cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term effects of medical management on growth and weight in individuals with urea cycle disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. From genotype to phenotype: Early prediction of disease severity in argininosuccinic aciduria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Matthias Zielonka
  • Stefan Kölker
  • Florian Gleich
  • Nicolas Stützenberger
  • Sandesh C S Nagamani
  • Andrea L Gropman
  • Georg F Hoffmann
  • Sven F Garbade
  • Roland Posset
  • Urea Cycle Disorders Consortium (UCDC) and the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) Consortia Study Group
  • Allan Meldgaard Lund (Medlem af forfattergruppering)
Vis graf over relationer

OBJECTIVE: Citrullinemia type 1 (CTLN1) is an inherited metabolic disease affecting the brain which is detectable by newborn screening. The clinical spectrum is highly variable including individuals with lethal hyperammonemic encephalopathy in the newborn period and individuals with a mild-to-moderate or asymptomatic disease course. Since the phenotypic severity has not been predictable early during the disease course so far, we aimed to design a reliable disease prediction model.

METHODS: We used a newly established mammalian biallelic expression system to determine residual enzymatic activity of argininosuccinate synthetase 1 (ASS1; OMIM #215700) in 71 individuals with CTLN1, representing 48 ASS1 gene variants and 50 different, mostly compound heterozygous combinations in total. Residual enzymatic ASS1 activity was correlated to standardized biochemical and clinical endpoints available from the UCDC and E-IMD databases.

RESULTS: Residual enzymatic ASS1 activity correlates with peak plasma ammonium and L-citrulline concentrations at initial presentation. Individuals with 8% of residual enzymatic ASS1 activity or less had more frequent and more severe hyperammonemic events and lower cognitive function than those above 8%, highlighting that residual enzymatic ASS1 activity allows reliable severity prediction. Noteworthy, empiric clinical practice of affected individuals is in line with the predicted disease severity supporting the notion of a risk stratification-based guidance of therapeutic decision-making based on residual enzymatic ASS1 activity in the future.

INTERPRETATION: Residual enzymatic ASS1 activity reliably predicts the phenotypic severity in CTLN1. We propose a new severity-adjusted classification system for individuals with CTLN1 based on the activity results of the newly established biallelic expression system.

OriginalsprogEngelsk
TidsskriftAnnals of Clinical and Translational Neurology
Vol/bind6
Udgave nummer9
Sider (fra-til)1858-1871
Antal sider14
ISSN2328-9503
DOI
StatusUdgivet - 2019

Bibliografisk note

© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

ID: 58997425